Ardena meets the growing demand for bioanalytical testing services
Ardena (Ghent, Belgium) has announced a significant expansion of its bioanalytical services in the Netherlands to meet rising client demands and support comprehensive drug development.
Ardena, a leading pharmaceutical CDMO, has recently announced a significant expansion of its bioanalytical services in the Netherlands, reinforcing its position as an industry frontrunner. With Good Manufacturing Practice (GMP) facilities spread across Sweden, Spain, Belgium and the Netherlands, the company is investing heavily in a state-of-the-art bioanalytical lab at its Pivot Park location in Oss (Netherlands), as well as boosting the capabilities of its Bioanalytical Center of Excellence in Assen (Netherlands). This strategic move aims to cater to the growing global demand for extensive and advanced bioanalytical solutions for various stages of drug development.
In 2023, the bioanalytical services market size was valued at US $3.57 billion [1], and this number is expected to double in the next 8 years. What is driving such significant growth you ask? Mainly the fuel of ~10,000 drugs being developed globally, which require advanced analytical tools and techniques for preclinical and clinical testing. In an effort to meet this need, CROs and CDMOs are rapidly increasing in number and capacity. Many hands make light work after all, and Ardena is one of the latest CDMOs to upgrade their equipment and infrastructure.
Specializing in the advanced development of innovative and complex drug molecules, Ardena will further enhance its comprehensive suite of services for biopharmaceutical companies, including solid state chemistry, active pharmaceutical ingredient services, nanomedicine development, analytical and formulation expertise, drug product manufacturing and CMC regulatory and bioanalytical support.
Scheduled to open by Q1 2025, the new lab in Oss is over 3,000 square feet and will feature the latest technology for analytical testing of both small and large molecules. This includes advanced LC–MS/MS and fluorometric detection assays, alongside the ELISA-based Gyrolab® automated immunoassay platform. In parallel, Ardena’s Assen facility is receiving an upgrade with enhanced qPCR, immunochemistry and flow cytometry capabilities, as well as additional LC–MS/MS systems and new Hamilton® automated equipment to streamline processes and tackle evolving bioanalytical challenges.
The enhanced capabilities will support the development of therapeutic modalities from discovery to late-stage clinical phases, including small molecules, therapeutic proteins, antibodies, nanoparticles, oligonucleotides, mRNA, antibody-drug conjugates and cell and gene therapies.
“These investments highlight Ardena’s commitment to growth and innovation, strengthening our ability to guide clients through the increasingly complex landscape of drug development and deliver transformative therapies to patients more efficiently,” explained Jeremie Trochu, Chief Executive Officer of Ardena.
With these strategic enhancements, Ardena continues to position itself as a key partner for biotech and pharma to accelerate the journey from drug discovery to clinical application.
